The identification of novel genetic variants in ncRNAs and their targets associated with T2DM and its complications, with a deep analysis of ncRNA profiles and functions in monocytes and macrophages in the context of SGLT2-i treatment, are needed to develop accurate predictive algorithms for personalized therapy of T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.